B
Baicare
Baicare is an automated nucleic acid detection system developer
About Baicare
Baicare operates in the medical diagnostics industry, specializing in the development and distribution of advanced QPCR (Quantitative Polymerase Chain Reaction) detection systems. The company's flagship product, the Baicare Ultrafast QPCR Detection System FQ 8A, utilizes real-time fluorescent quantitative PCR technology combined with dynamic temperature control to enable rapid and accurate nucleic acid detection. This system is designed to be compact and portable, making it suitable for a variety of settings, including laboratories and point-of-care environments.
Baicare's primary clients include healthcare providers, diagnostic laboratories, and research institutions that require efficient and reliable tools for DNA and RNA amplification and detection. The company operates in a highly specialized market focused on molecular diagnostics, with a particular emphasis on infectious disease detection, including COVID-19.
The business model is centered around the sale of its QPCR detection systems, along with associated reagents and consumable items. Revenue is generated through direct sales to end-users, as well as through partnerships and distribution agreements with medical equipment suppliers. Baicare's products are designed to offer ease of use, speed, and safety, featuring an anti-pollution open lid design to ensure contamination-free operations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Dongcheng District, China
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Health Diagnostics, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCEquity / VC | Mar 2022 | $14M | $55M | Undisclosed | — |
| OtherOther financing | Oct 2021 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Baicare is 170 monthly website visits, down 81.3% over the last three months. Baicare's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- RCRobust Cloud
- SCSinopharm Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Baicare on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Baicare’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.